Please login to the form below

Not currently logged in
Email:
Password:

cangrelor

This page shows the latest cangrelor news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

cangrelor. Kengrexal. percutaneous coronary intervention (PCI). P2Y12 inhibitor. The Medicines Company.

Latest news

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    Kengreal (cangrelor) has been approved by the FDA for adult patients undergoing percutaneous coronary intervention (PCI) to open a blocked or narrowed coronary artery, three months after being given a green ... TMC's efforts to bring cangrelor to market

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    Cangrelor go-ahead. Meanwhile, the FDA's advisory committee also voted 9 to 2 in favour of approving The Medicines Company's injectable anticoagulant cangrelor as an adjunct to percutaneous coronary ... The FDA is due to deliver a final decision on

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    FDA reviewer backs approval of TMC's cangrelor. Claims it offers a small benefit over Sanofi’ s Plavix. ... Analysts had at one point been predicting sales of cangrelor could reach upwards of $500m, but expectations are now more modest with estimates

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Kengrexal (cangrelor) was recommended for use in the reduction of thrombotic cardiovascular events in adults with coronary artery disease.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics